

# Roberto Marasca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5473727/publications.pdf>

Version: 2024-02-01

238  
papers

10,401  
citations

38742

50  
h-index

38395

95  
g-index

242  
all docs

242  
docs citations

242  
times ranked

10131  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1389-1401.	8.5	565
2	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	1.4	420
3	Mutations of <i>NOTCH1</i> are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 521-529.	1.4	394
4	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012, 209, 1537-1551.	8.5	363
5	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401.	1.4	316
6	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	1.6	302
7	Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 468-473.	1.6	241
8	Bone Marrow Failure Associated with Human Herpesvirus 8 Infection after Transplantation. <i>New England Journal of Medicine</i> , 2000, 343, 1378-1385.	27.0	224
9	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682.	1.4	208
10	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	1.4	207
11	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198
12	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
13	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
14	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	3.5	193
15	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.	7.0	189
16	<i>NOTCH1</i> mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. <i>Haematologica</i> , 2012, 97, 437-441.	3.5	178
17	Alteration of <i>BIRC3</i> and multiple other <i>NF-<math>\kappa</math>B</i> pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011, 118, 4930-4934.	1.4	176
18	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	1.4	173

#	ARTICLE	IF	CITATIONS
19	Three cases of human herpesvirus-6 latent infection: Integration of viral genome in peripheral blood mononuclear cell DNA. <i>Journal of Medical Virology</i> , 1993, 40, 44-52.	5.0	169
20	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. <i>Blood</i> , 2006, 107, 2889-2894.	1.4	167
21	Immunoglobulin Gene Mutations and Frequent Use of VH1-69 and VH4-34 Segments in Hepatitis C Virus-Positive and Hepatitis C Virus-Negative Nodal Marginal Zone B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2001, 159, 253-261.	3.8	148
22	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	1.4	147
23	Expression of Human Herpesvirus-6 Antigens in Benign and Malignant Lymphoproliferative Diseases. <i>American Journal of Pathology</i> , 1998, 153, 815-823.	3.8	145
24	Human Herpesvirus 6 Latently Infects Early Bone Marrow Progenitors In Vivo. <i>Journal of Virology</i> , 1999, 73, 754-759.	3.4	122
25	Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. <i>British Journal of Haematology</i> , 1996, 94, 373-375.	2.5	121
26	Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. <i>Journal of Medical Virology</i> , 1995, 46, 178-188.	5.0	117
27	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	1.4	113
28	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	2.5	106
29	Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. <i>Blood</i> , 2011, 118, 5416-5419.	1.4	102
30	Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 917-919.	1.9	99
31	Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. <i>Blood</i> , 2002, 99, 1482-1485.	1.4	94
32	Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. <i>Annals of Oncology</i> , 1998, 9, 495-498.	1.2	93
33	The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. <i>Haematologica</i> , 2013, 98, 1115-1123.	3.5	92
34	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	3.5	91
35	Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2012, 158, 426-429.	2.5	90
36	Human herpesvirus-6: A survey of presence and distribution of genomic sequences in normal brain and neuroglial tumors. <i>Journal of Medical Virology</i> , 1995, 47, 105-111.	5.0	84

#	ARTICLE	IF	CITATIONS
37	The KrÄ4ppl-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	7.2	84
38	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 65968-65981.	1.8	84
39	<i>MGA</i>, a suppressor of<i>MYC</i>, is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1087-1090.	1.3	81
40	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. <i>PLoS ONE</i> , 2013, 8, e83830.	2.5	80
41	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 529-537.	2.5	78
42	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
43	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	2.8	67
44	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	5.2	66
45	p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. <i>Journal of Pathology</i> , 1995, 176, 45-53.	4.5	65
46	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
47	Comprehensive characterization of IGHV3-21â€expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	1.4	62
48	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014, 28, 642-648.	7.2	57
49	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
50	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	1.7	55
51	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	1.4	53
52	Frequent detection of human herpesvirus-6 sequences by polymerase chain reaction in paraffin-embedded lymph nodes from patients with angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. <i>Leukemia Research</i> , 1993, 17, 1003-1011.	0.8	52
53	Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3492.	4.1	52
54	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592.	1.4	51

#	ARTICLE	IF	CITATIONS
55	Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib. <i>Journal of Hematology and Oncology</i> , 2015, 8, 60.	17.0	49
56	BCR-ABL <sup>+</sup> -specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. <i>Blood</i> , 2017, 129, 582-586.	1.4	49
57	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	1.4	49
58	Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. <i>Leukemia Research</i> , 2010, 34, 312-321.	0.8	48
59	Characterization of Specific Immune Responses to Different <i>Aspergillus</i> Antigens during the Course of Invasive Aspergillosis in Hematologic Patients. <i>PLoS ONE</i> , 2013, 8, e74326.	2.5	48
60	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. <i>Blood</i> , 2000, 96, 2355-2357.	1.4	46
61	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	7.0	44
62	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, .	6.0	43
63	Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with <i>Flt3</i> mutational status. <i>Leukemia</i> , 2006, 20, 103-114.	7.2	42
64	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	3.5	42
65	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009, 7, 76.	4.4	41
66	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599.	2.5	40
67	Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 253-262.	3.5	40
68	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	1.4	40
69	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016, 11, e0149108.	2.5	40
70	Frequency and distribution of herpesvirus-like DNA sequences (KSHV) in different stages of classic Kaposi's sarcoma and in normal tissues from an Italian population. , 1996, 66, 427-431.		39
71	correspondence: Pregnancy in PNH: another eculizumab baby. <i>British Journal of Haematology</i> , 2010, 150, 707-708.	2.5	37
72	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011, 118, 5759-5766.	1.4	34

#	ARTICLE	IF	CITATIONS
73	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	2.5	33
74	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	1.4	33
75	A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 652-652.	1.4	33
76	Investigating the association between physicians self-efficacy regarding communication skills and risk of "burnout". <i>Health and Quality of Life Outcomes</i> , 2020, 18, 271.	2.4	32
77	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	2.5	30
78	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99.	1.7	30
79	<i>ANGPT2</i> promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2013, 8, 720-729.	2.7	30
80	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	1.3	30
81	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	3.5	30
82	BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 2158.	4.8	30
83	Circulating endothelial cells in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 1926-1937.	4.1	29
84	Physical contact with endothelial cells through $\alpha 1$ - and $\alpha 2$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. <i>Haematologica</i> , 2012, 97, 952-960.	3.5	29
85	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. <i>Blood Reviews</i> , 2020, 40, 100635.	5.7	29
86	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	3.5	29
87	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2011, 152, 284-294.	2.5	28
88	NOX-A12: mobilizing CLL away from home. <i>Blood</i> , 2014, 123, 952-953.	1.4	28
89	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <i>Cancers</i> , 2021, 13, 4582.	3.7	28
90	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. <i>American Journal of Hematology</i> , 2017, 92, 82-87.	4.1	27

#	ARTICLE	IF	CITATIONS
91	NPM1-Mutated Myeloid Neoplasms with <math>\geq 20\%</math> Blasts: A Really Distinct Clinico-Pathologic Entity?. International Journal of Molecular Sciences, 2020, 21, 8975.	4.1	26
92	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematological Oncology, 2013, 31, 88-95.	1.7	25
93	Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. Oncotarget, 2019, 10, 869-882.	1.8	25
94	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Experimental Hematology, 2014, 42, 126-136.e1.	0.4	23
95	NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Leukemia and Lymphoma, 2015, 56, 3222-3226.	1.3	23
96	Expression of Cell-Homologous Genes of Human Herpesvirus-8 in Human Immunodeficiency Virus-Negative Lymphoproliferative Diseases. Blood, 1999, 94, 2931-2933.	1.4	22
97	Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leukemia Research, 2008, 32, 593-597.	0.8	22
98	Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. European Journal of Haematology, 2011, 86, 352-355.	2.2	22
99	BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood, 2001, 97, 2187-2189.	1.4	21
100	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. Journal of Translational Medicine, 2012, 10, 18.	4.4	21
101	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	2.5	20
102	Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis. Clinical and Developmental Immunology, 2012, 2012, 1-9.	3.3	20
103	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. Hematological Oncology, 2012, 30, 46-49.	1.7	20
104	Might Essential Thrombocythemia Carry Ph Anomaly?. Blood, 1998, 91, 3084-3085.	1.4	19
105	Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica, 2008, 93, 1252-1255.	3.5	19
106	Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. British Journal of Haematology, 2011, 153, 351-357.	2.5	19
107	Promoter methylation patterns in <math>R</math>-ichter syndrome affect stem cell maintenance and cell cycle regulation and differ from <i>de novo</i> diffuse large <math>B</math>-cell lymphoma. British Journal of Haematology, 2013, 163, 194-204.	2.5	19
108	Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments. Cells, 2021, 10, 217.	4.1	19



#	ARTICLE	IF	CITATIONS
109	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. International Journal of Molecular Sciences, 2021, 22, 1906.	4.1	19
110	HHV-8-associated primary cerebral B-cell lymphoma in HIV-negative patient after long-term steroids. Lancet, The, 1996, 347, 980.	13.7	18
111	Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia. Leukemia, 2002, 16, 955-956.	7.2	18
112	The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of <i>PDGFRB</i> partner genes. Leukemia and Lymphoma, 2017, 58, 489-493.	1.3	18
113	Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. Blood, 2011, 118, 1359-1359.	1.4	17
114	Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. Haematologica, 2018, 103, e598-e601.	3.5	16
115	Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up. Blood, 2015, 126, 510-510.	1.4	16
116	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 687-687.	1.4	15
117	Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. Leukemia, 2007, 21, 1312-1315.	7.2	14
118	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica, 2012, 97, 849-853.	3.5	14
119	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Annals of Oncology, 2013, 24, 1378-1384.	1.2	13
120	First report of <i>FIP1L1-PDGFR</i>-positive eosinophilic granulomatosis with polyangiitis : Fig. 1. Rheumatology, 2015, 54, 1751-1753.	1.9	13
121	IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. Leukemia, 2021, 35, 1330-1343.	7.2	13
122	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. Blood, 2012, 120, 200-200.	1.4	13
123	Human Herpesvirus-6 Genome in Acute Lymphoblastic Leukemia: Evidence against an Etiologic Relationship. Acta Haematologica, 1995, 94, 169-172.	1.4	12
124	Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia. Journal of Molecular Diagnostics, 2005, 7, 566-574.	2.8	12
125	BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab. European Journal of Haematology, 2008, 81, 244-245.	2.2	12
126	Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2016, 97, 291-302.	4.4	12



#	ARTICLE	IF	CITATIONS
127	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
128	Early palliative/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002898.	1.6	12
129	Relationship Between BCR/ABL Fusion Proteins and Leukemia Phenotype. <i>Blood</i> , 1997, 89, 3889-3889.	1.4	11
130	Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. <i>Leukemia</i> , 2008, 22, 628-631.	7.2	11
131	Detection of PML-RAR $\alpha$ fusion transcript in Ph positive leukemia with acute promyelocytic phenotype lacking the t(15;17) cytogenetic abnormality. <i>Cancer Genetics and Cytogenetics</i> , 1995, 80, 95-99.	1.0	10
132	Hepatitis C virus-induced leuko-thrombocytopenia and haemolysis. , 1997, 53, 182-184.		10
133	Lenalidomide in Pretreated Patients with Diffuse Large Bâ€Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	3.7	10
134	Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS. <i>Leukemia</i> , 2019, 33, 1278-1302.	7.2	10
135	Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1081.	4.1	10
136	Chronic myeloid leukemia with thrombocythemic onset may be associated with different BCR/ABL variant transcripts. <i>Cancer Genetics and Cytogenetics</i> , 1998, 101, 75-77.	1.0	9
137	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010, 51, 822-838.	1.3	9
138	Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma. <i>Haematologica</i> , 2015, 100, e467-e470.	3.5	9
139	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	3.5	9
140	Management of chronic lymphocytic leukemia in Italy during a one year of the COVIDâ€19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	1.7	9
141	Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1. <i>Frontiers in Oncology</i> , 2021, 11, 777587.	2.8	9
142	P53 Gene Mutations in Chronic Myelogenous Leukemia Medullary and Extramedullary Blast Crisis. <i>Leukemia and Lymphoma</i> , 1996, 24, 175-182.	1.3	8
143	Longâ€term molecular remission with persistence of <i><sc>BCR</sc>â€<sc>ABL</sc> 1</i>-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphiaâ€positive <sc>ALL</sc>. <i>British Journal of Haematology</i> , 2014, 164, 299-302.	2.5	8
144	The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. <i>Leukemia Research</i> , 2017, 54, 17-24.	0.8	8

#	ARTICLE	IF	CITATIONS
145	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	1.7	8
146	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , 2014, 124, 705-705.	1.4	8
147	Late-Appearing PML/RAR $\alpha$ Fusion Transcript with Coincidental t(12;13)(p13.2;q14) in Acute Promyelocytic Leukemia Lacking the t(15;17) Cytogenetic Anomaly. <i>Cancer Genetics and Cytogenetics</i> , 2000, 119, 121-126.	1.0	7
148	All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 1138-1146.	0.5	7
149	Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis. <i>Journal of Infection</i> , 2017, 74, 314-318.	3.3	7
150	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	1.3	7
151	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9159.	4.1	7
152	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585.	1.4	7
153	A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). <i>Journal of Clinical Oncology</i> , 2015, 33, 8573-8573.	1.6	7
154	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. <i>Cells</i> , 2022, 11, 1003.	4.1	7
155	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5242.	4.1	7
156	The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. <i>Annals of Oncology</i> , 1999, 10, 467-469.	1.2	6
157	HUMAN HERPESVIRUS-6 (HHV-6) IN BLOOD DONORS. <i>British Journal of Haematology</i> , 1995, 89, 943-945.	2.5	6
158	May the Indirect Effects of CMV in Transplant Patients be Exerted Through the Reactivation of the Viral Replicative Machinery?. <i>Transplantation</i> , 2011, 92, e49-e51.	1.0	6
159	Severe anemia in a patient with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2014, 83, 374-375.	1.1	6
160	Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6 reactivation. <i>British Journal of Haematology</i> , 2016, 172, 561-572.	2.5	6
161	Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. <i>Haematologica</i> , 2021, 106, 2265-2268.	3.5	6
162	How to Improve Prognostication in Acute Myeloid Leukemia with CBF $\beta$ -MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. <i>Biomedicines</i> , 2021, 9, 953.	3.2	6

#	ARTICLE	IF	CITATIONS
163	Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation. <i>Frontiers in Immunology</i> , 2022, 13, 832263.	4.8	6
164	Lack of confirmation of an association between HTLV-I infection and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1999, 105, 1146-1147.	2.5	5
165	Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2207-2208.	1.3	5
166	Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study. <i>Annals of Hematology</i> , 2015, 94, 1931-1934.	1.8	5
167	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , 2021, 39, 707-711.	1.7	5
168	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 90013-90027.	1.8	5
169	Double P53 Point Mutation in Extramedullar Blast Crisis of Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 16, 171-175.	1.3	4
170	Vorinostat interferes with Wnt and NF- $\kappa$ B pathways in the M-07e cell line. <i>Leukemia</i> , 2009, 23, 1935-1938.	7.2	4
171	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.8	4
172	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	2.7	4
173	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611.	1.4	4
174	Peripheral lymphadenopathy: role of excisional biopsy in differential diagnosis based on a five-year experience. <i>Minerva Chirurgica</i> , 2019, 74, 218-223.	0.8	4
175	Angiopoietin-2 Expression in B-Cell Chronic Lymphocytic Leukemia: Association with Clinical Outcome and Immunoglobulin Heavy-Chain Mutational Status.. <i>Blood</i> , 2006, 108, 2780-2780.	1.4	4
176	Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: An ex vivo study. <i>Leukemia Research</i> , 2008, 32, 1324-1325.	0.8	3
177	Atraumatic splenic rupture in patients with myelodysplastic syndromes: Report of a case occurred during treatment with 5-azacitidine and review of the literature. <i>Leukemia Research</i> , 2012, 36, e52-e56.	0.8	3
178	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038.	3.7	3
179	Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study. <i>Leukemia and Lymphoma</i> , 2018, 59, 225-228.	1.3	3
180	Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study. <i>Annals of Hematology</i> , 2020, 99, 2201-2203.	1.8	3

#	ARTICLE	IF	CITATIONS
181	Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMVâ€¦ prophylaxis: A monocentric retrospective analysis. <i>Journal of Medical Virology</i> , 2021, 93, 6292-6300.	5.0	3
182	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. <i>Blood</i> , 2015, 126, 3946-3946.	1.4	3
183	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	1.4	3
184	NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4280-4280.	1.4	3
185	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	3.7	3
186	Polymerase Chain Reaction Detection of Human Herpesvirus 8 Sequences in Primary Central Nervous System Lymphomas. <i>Journal of Infectious Diseases</i> , 1998, 177, 520-520.	4.0	2
187	The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi. <i>Medical Mycology</i> , 2016, 54, 327-332.	0.7	2
188	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 2018-2021.	1.3	2
189	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	1.4	2
190	Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study. <i>Blood</i> , 2008, 112, 3167-3167.	1.4	2
191	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010, 116, 1371-1371.	1.4	2
192	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. <i>Blood</i> , 2013, 122, 1645-1645.	1.4	2
193	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.	1.4	2
194	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
195	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	5.2	2
196	Spontaneous loss of ph chromosome with maintenance of clonal hemopoiesis in an untreated patient with myeloproliferative disease and a long survival. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 237-240.	2.8	1
197	<i>IGHD3â€¦</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 299-302.	2.5	1
198	A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. <i>Leukemia and Lymphoma</i> , 2011, 52, 2012-2019.	1.3	1

#	ARTICLE	IF	CITATIONS
199	Characterization of Duvelisib in Patients with Refractory Marginal Zone Lymphoma: Data from the Phase 2 DYNAMO Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S312-S313.	0.4	1
200	Selective inhibition of PI3K $\hat{I}^3$ affects survival and proliferation of chronic lymphocytic leukemia B cells. <i>Leukemia and Lymphoma</i> , 2020, 61, 455-459.	1.3	1
201	Incidence and Outcome of Myelodysplastic Syndromes in Province of Modena.. <i>Blood</i> , 2007, 110, 4610-4610.	1.4	1
202	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014, 124, 3074-3074.	1.4	1
203	Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features.. <i>Blood</i> , 2009, 114, 1256-1256.	1.4	1
204	Alteration of BIRC3 and Multiple Other NF- $\hat{I}^B$ Pathway Genes in Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2011, 118, 264-264.	1.4	1
205	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263.	1.4	1
206	The PI3 Kinase $\hat{I}$ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures.. <i>Blood</i> , 2011, 118, 1769-1769.	1.4	1
207	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study. <i>Blood</i> , 2018, 132, 3147-3147.	1.4	1
208	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021, 138, 3746-3746.	1.4	1
209	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
210	Mutations of the <i>XPO1</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. $\hat{I}$ Training/Validation Study. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
211	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. <i>Blood Cancer Journal</i> , 2022, 12, 79.	6.2	1
212	Gestational thrombocytopenia. <i>Lancet, The</i> , 2000, 356, 1355.	13.7	0
213	An unusual case of B-ALL occurring in a patient with acute promyelocytic leukemia in remission after two hematopoietic SCTs: whose are the leukemic cells?. <i>Bone Marrow Transplantation</i> , 2014, 49, 1237-1238.	2.4	0
214	Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S11-S12.	0.4	0
215	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e9.	0.4	0
216	Angiopoietin $\hat{I}^2$ acts as a survival factor for chronic lymphocytic leukemia <i>B</i> cells throughout <i>T</i> receptor engagement. <i>Hematological Oncology</i> , 2018, 36, 372-375.	1.7	0

#	ARTICLE	IF	CITATIONS
217	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e321-e323.	0.4	0
218	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007, 110, 3089-3089.	1.4	0
219	Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.. <i>Blood</i> , 2007, 110, 4686-4686.	1.4	0
220	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Blood</i> , 2008, 112, 778-778.	1.4	0
221	Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 1260-1260.	1.4	0
222	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. <i>Blood</i> , 2009, 114, 760-760.	1.4	0
223	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3578-3578.	1.4	0
224	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. <i>Blood</i> , 2010, 116, 3601-3601.	1.4	0
225	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 712-712.	1.4	0
226	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. <i>Blood</i> , 2013, 122, 77-77.	1.4	0
227	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	1.4	0
228	Lenalidomide Promotes a Pro-Inflammatory Switch of Nurse-like Cells Derived from Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3286-3286.	1.4	0
229	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3300-3300.	1.4	0
230	Ibrutinib Targets Nurse-like Cells Supporting an Immunosuppressive Phenotype in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 613-613.	1.4	0
231	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.	1.4	0
232	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. <i>Blood</i> , 2016, 128, 3076-3076.	1.4	0
233	New players in the Brutonâ€™s tyrosine kinase vs. ibrutinib match. <i>Translational Cancer Research</i> , 2017, 6, S469-S471.	1.0	0
234	Casein kinase 1: a new tale of chronic lymphocytic leukemia (CLL) microenvironment. <i>Translational Cancer Research</i> , 2018, 7, S730-S732.	1.0	0

#	ARTICLE	IF	CITATIONS
235	Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. <i>Leukemia Research</i> , 2021, 111, 106747.	0.8	0
236	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	1.4	0
237	Indoleamine 2,3-Dioxygenase Mediates Survival of Chronic Lymphocytic Leukemia B Cells through Aryl Hydrocarbon Receptor By Inducing Mcl1. <i>Blood</i> , 2020, 136, 19-19.	1.4	0
238	PEG-Asparaginase Single-Agent Rescue in an Advanced Case of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 304-308.	1.3	0